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Abstract
Background: PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling
and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1
is an important promoter of migration and invasion in breast cancer. This study aims to evaluate the utility of
PPFIA1 expression in the luminal breast cancer as a prognostic marker to predict the response to endocrine
therapy.
Methods: Large, well-characterised cohorts of primary luminal breast cancer patients with long-term follow-up was
assessed for the clinical impact of PPFIA1 expression at the transcriptomic and proteomic levels. Prognostic
significance of PPFIA1 and its relationship with clinical outcome and benefit of endocrine therapy were analysed. In
addition, its association with other related-genes was analysed.
Results: There was significant association between PPFIA1 expression and a member of the liprin family that
involves in cell invasion (PPFIBPI), and the cell cycle regulator (CCND1), whereas a negative association was observed
with the tumour suppressor gene (CD82). Patients with high PPFIA1 expression were associated with high risk of
recurrence, distant metastasis and death from breast cancer (P < 0.05). Importantly, high PPFIA1 expression
predicted relapse in a subset of patients who were subject to endocrine treatment alone, and was an independent
prognostic marker of unfavourable outcome in these patients (P < 0.05).
Conclusions: These findings support the proposed role for PPFIA1 as a regulator of cell migration in breast cancer
and provides definitive evidence for the clinical utility of PPFIA1 expression in patients with luminal breast cancer.
Most importantly, our data suggests that PPFIA1 might be a potential predictive marker for poor benefit from
endocrine therapy.
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Background
Breast cancer exhibits significant heterogeneity with differ-
ent molecular subtypes, and the main subtype of the disease
are luminal, Estrogen Receptor positive (ER+)/HER2-nega-
tive, tumours which account approximately 75% of all
breast cancers. This subtype remains heterogeneous in
terms of prognosis and response to treatment [1, 2]. Endo-
crine therapy remains the key treatment for luminal breast
cancer, whereas a small proportion of these tumours that
are associated with high risk are offered chemotherapy. Al-
though this treatment can potentially reduce the mortality
rate, patients with similar prognostic factors at diagnosis
can vary substantially in their response to treatment, de-
velop resistance and later relapse [3, 4]. Therefore, identify-
ing reliable predictive biomarkers for endocrine therapy
benefit is required to stratify patients with luminal tumours
for alternative therapy.
PTPRF Interacting Protein Alpha 1 (PPFIA1), also
known as liprin-α1, belongs to the liprin family that in-
cludes liprin-α and liprin-β proteins [5]. PPFIA1 can inter-
act directly with its several partners, and might form
homo- or hetero-dimers with liprin-β proteins. PPFIA1
was originally found to control synapse formation and
function in neuronal cells [6], whereas in non-neuronal
cells it has been implicated in the regulation of cell motil-
ity [7]. Tumour cell migration and extracellular matrix
degradation is required for tumour cells to form tumour
metastasis [8], and recent studies suggest that PPFIA1 is
an important promoter of tumour cells spreading in the
extracellular matrix and is required for migration and in-
vasion of tumour cells including breast cancer [9, 10].
PPFIA1 is located at the 11q13 amplification region, and
is amplified in about 20% of breast cancer [11].
In this study, we hypothesised that PPFIAI will play a
role in breast cancer and can provide important prog-
nostic information that may help to risk stratify luminal
tumors with respect to endocrine therapy.
PPFIA1 expression was assessed at the transcriptomic
and proteomic levels utilising large and well-characterised
annotated cohorts of luminal breast cancer.
Methods
PPFIA1 mRNA expression
PPFIA1 transcriptomic expression in luminal breast can-
cer and its role in predicting response to endocrine
treatment was assessed in; The Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC)
[12], Kaplan Meier Plotter-Breast Cancer (KM-Plotter)
dataset [13] and Breast Cancer Gene-Expression Miner
v4.3 (bc-GenExMiner v4.3) [14]. Additionally, the correl-
ation of PPFIA1 with other related-genes was investi-
gated. The METABRIC cohort characteristics are in
Supplementary Table 1.
Protein expression cohort
PPFIA1 protein expression was assessed in a well-
characterised series of luminal primary invasive breast can-
cer patients, with long-term follow-up (n = 521). Patients
were presented at Nottingham City Hospital (1989–2006),
as previously described [15]. The cohort characteristics are
summarised in Supplementary Table 1.
Evaluation of PPFIA1 protein expression
The specificity of the PPFIA1 antibody (1500; A10388,
ABclonal, UK) was validated by Western blotting using
BT474 human breast cancer cell lysate (American Type Cul-
ture Collection; Rockville, MD, USA), which showed a single
band of approximately the predicted size (135 kDa) (Fig. 1a).
PPFIA1 protein expression was evaluated using immu-
nohistochemistry (IHC) on 4-μm tissue microarray
(TMA) sections using Novolink polymer detection system
(RE7150-K, Leica Biosystems, UK), as previously described
using the PPFIA1 antibody at 1:100 dilution (A10388,
ABclonal, UK) [15]. Evaluation of cytoplasmic staining for
PPFIA1 in invasive tumour cells was performed using the
modified histochemical score (H-score) [16]. TMA cores
were only assessed if invasive tumour burden was > 15%.
The PR positivity was defined as ≥ 1% staining.
Statistical analysis
SPSS (version 25, Chicago, IL, USA) was used for all
statistical analysis. The Chi-square test was used to
evaluate the association between PPFIA1 mRNA/protein
expression and clinicopathological parameters. To test
correlation between two continuous normalised data,
Pearson’s correlation coefficient was used. For the con-
tinuous variables, differences in mean between three or
more groups were assessed using one-way analysis of
variance (ANOVA) with the post-hoc Tukey multiple
comparison test. T-test was used to assess the difference
between two groups. Kaplan-Meier survival curves were
used to investigate the association of PPFIA1 mRNA/
protein expression with clinical outcome. The endpoint
outcomes were breast cancer, recurrence and distant
metastasis free survival. Cox regression analysis was used
to evaluate the independent prognostic significance of
PPFIA1 mRNA/protein expression. The Benjamini–
Hochberg procedure for multiple test correction was
used. Dichotomisation of PPFIA1 mRNA/protein expres-
sion into groups was determined using X-Tile (X-Tile
Bioinformatics Software, Yale University, version 3.6.1).
A p value of <0.05 was considered significant.
Results
PPFIA1 expression
Protein expression of PPFIA1 was observed in the cyto-
plasm of luminal tumours, and a representative images
of IHC staining are shown in (Fig. 1b and c). High
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PPFIA1 protein expression (> 15 H-score) was observed
in 394/521 (76%) of cases in luminal tumours, while high
expression of PPFIA1 mRNA was observed in 1129/1398
(81%) of cases in the METABRIC cohort.
High PPFIA1 mRNA expression was associated with
high tumour grade and the development of distant metas-
tasis to the liver, brain, bone and lung (P < 0.05; Fig. 1d-h).
However, the association between PPFIA1 protein expres-
sion with other clinicopathological parameters did not
reach statistical significance, Supplementary Table 2.
Prognostic value of PPFIA1 expression
In the METABRIC cohort, patients showing high ex-
pression of PPFIA1 were statistically associated to
shorter survival (P = 0.01; Fig. 2a) in compared with
those showing low expression, which showed better clin-
ical outcome. This association was confirmed using the
KM-Plotter and bc-GenExMiner v4.3 datasets (P <
0.0001; Supplementary Figure 1A and B).
Likewise, results using the METABRIC cohort revealed
that patients with tumours that highly expressed PPFIA1
mRNA significantly associated with poor recurrence and dis-
tant metastasis than those with low PPFIA1 expression (P <
0.05; Fig. 2b and c). These results were further validated
using KM-Plotter and bc-GenExMiner v4.3 datasets, where
higher levels of PPFIA1 mRNA were correlated to unfavour-
able outcome (P < 0.0001; Supplementary Figure 1C-E). This
is consistent with what we found in the analysis of protein
expression, whereby patients with high PPFIA1 protein ex-
pression had worse recurrence free survival compared to
those with low PPFIA1 expression (P = 0.01; Fig. 2d).
PPFIA1 expression predicts poor response to endocrine
therapy
We next compared the levels of PPFIA1 mRNA expression
between patients who received endocrine treatment and
relapsed (unresponsive) with patients who received endo-
crine treatment but did not relapse (responsive). Results
showed that PPFIA1 mRNA was highly expressed in unre-
sponsive patients in comparison to those who responded
to adjuvant endocrine therapy (P < 0.0001; Fig. 3a).
In patients who were subject to endocrine treat-
ment only, high PPFIA1 mRNA was found to be
significantly correlated with shorter recurrence, dis-
tant metastasis and survival (P < 0.05; Fig. 3b-d).
This finding was further validated using KM-Plotter
dataset (P < 0.05; Supplementary Figure 2A-C). In
confirmation, patients receiving endocrine therapy
Fig. 1 a Western blotting result for PPFIA1 expression in BT474 breast cancer cell lysate. Full-length blot is presented in Supplementary Figure 3.
Representative immunostaining images of invasive breast cancer using IHC b) negative and c) positive for PPFIA1 protein expression. Association
of PPFIA1 mRNA expression with d) tumour grade. The difference in PPFIA1 mRNA expression between cases who either developed distant
metastasis to the e) liver f) Brain g) Bone and h) Lung or not, using the METABRIC cohort
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with high PPFIA1 protein expression had a worse
clinical outcome than those with low PPFIA1 ex-
pression (P = 0.04; Fig. 3d).
To further investigate the independence of PPFIA1 as a
potential marker for outcome, multivariate cox regression
analysis was performed. Results demonstrated that PPFIA1
mRNA expression was a predictor of poor outcome (P <
0.05), Supplementary Table 3. Further analysis on a sub-
group of patients who were subject to endocrine treatment
alone, demonstrated that PPFIA1 mRNA trend to be signifi-
cant marker for relapse (P = 0.05), Supplementary Table 3.
However, PPFIA1 protein expression, still an independent
prognostic marker for clinical outcome in those patients re-
ceiving endocrine treatment (P < 0.05), Table 1.
PPFIA1 expression and other associated genes
To further understand the potential roles of PPFIA1 in
luminal breast cancer and how it might affect the re-
sponse to the endocrine therapy, correlation of PPFIA1
mRNA expression with other associated-genes was in-
vestigated using the METABRIC cohort, and validated
using bc-GenExMiner v4.3 dataset, Supplementary
Table 4. The selection of these genes was based on pre-
vious publications, in which interact with PPFIA1 or
support its biological function [17–21]. Results showed a
positive correlation between PPFIA1 mRNA expression
and PPFIBPI, also known as (liprin-β1) which is member
of the liprin family that involves in cell invasion. Further,
a positive correlation was observed with the well-known
Fig. 2 Kaplan–Meier of PPFIA1 mRNA and patient outcome in luminal breast cancer using the METABRIC cohort a) survival b) recurrence and c)
distant metastasis. Kaplan–Meier of PPFIA1 protein and risk of d) recurrence
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cell cycle regulators (CCND1, CCNA2 and CCNB1). On
the other hand, a negative correlation was observed be-
tween PPFIA1 mRNA expression and integrin family
genes (ITGB1 and ITGA5) and the tumour suppressor
gene (CD82). Taken together, these findings suggest a
key role of PPFIA1 in the invasion of luminal tumours
and response to treatment.
Discussion
This study has explored the potential effects of PPFIA1
expression in luminal tumours. Our findings establish an
important role for PPFIA1 expression in luminal breast
cancer and response to endocrine therapy. This study of a
well-characterised cohort of clinically annotated patients
with early luminal breast cancer demonstrates that high
PPFIA1 expression associates with aggressive clinicopath-
ological parameters. Our study also confirmed that pa-
tients with high PPFIA1 expression had unfavourable
clinical outcome and poor response to endocrine therapy.
PPFIA1 is part of a multi-protein complex that is import-
ant in the regulation of tumour cell migration and invasion
[7, 10]. High expression of PPFIA1 has been reported in vari-
ous cancers including breast cancer [9, 11, 18, 22]. In support
of these findings, we found a proportion of breast cancers
with high mRNA and protein expression. In addition, we
found that PPFIA1 expression was associated with aggressive
clinicopathological parameters. Previous studies show a
contradictory role of PPFIA1 in regards to the invasiveness
of tumour cells, where silencing of PPFIA1 affects the regula-
tion of dynamic events associated with tumour cells invasion
[9, 17] whereas the effect is opposite in head and neck squa-
mous cell carcinoma [23]. However, our finding confirmed
an oncogenic role of PPFIA1 in tumour cell invasion where
we found high PPFIA1 levels is significantly correlated with
the development of distant metastasis in the liver. This result
ties well with previous study, which showed PPFIA1 expres-
sion was significantly higher in liver metastatic tumours than
in the primary tumours [24], and PPFIA1 overexpression en-
hanced cell spreading and cell migration [7]. Altogether,
these findings suggesting a potential role for PPFIA1 expres-
sion in the invasive process within breast tumour cells.
Another important finding of this study is that high
PPFIA1 expression is associated with short survival
within luminal breast cancer subtype. This is consistent
with a previous study where association of PPFIA1 amp-
lification with poor survival was only observed in the
subset of ER+ cancers with no prognostic effect on ER
negative or HER2+ breast cancer subtypes [18]. Indeed,
our results demonstrate the clinical role of PPFIA1 ex-
pression at both transcriptomic and proteomic levels in
predicting the recurrence and distant metastasis within
luminal breast cancer. These findings suggest critical
Fig. 3 a Shows the difference in PPFIA mRNA expression between responsive and unresponsive cases to endocrine treatment using METABRIC
cohort. Kaplan-Meier of PPFIA1 mRNA expression in patients with luminal breast cancer who received endocrine treatment only in the METABRIC
cohort b) recurrence c) distant metastasis and d) survival. Kaplan-Meier of PPFIA1 protein expression in patients with luminal breast cancer who
received endocrine treatment only e) survival
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roles of PPFIA1 in luminal breast cancer, and could be
used as a marker of poor prognosis.
Despite endocrine treatment has proven its enormous
value in the treatment of luminal breast cancer, resist-
ance stills a major issue in a proportion of these patients.
Therefore, it remains necessary to predict which patients
who will potentially benefit or resist this treatment
through identifying valuable clinical biomarkers to guide
choices of therapies [25]. ER and Progesterone Receptor
(PR) still the only used as a guide to response of endo-
crine treatment in clinic, despite the increase and wide-
spread of the advanced technology [26]. Multigene
signatures, such as Oncotype DX, EndoPredict and
Mammaprint can be used as additional prognostic tools
for risk stratification. However, these tools are unable to
predict patients’ benefit from anti-oestrogen treatment
in early stage, and in cases with intermediate score
which might lead to an inconclusive prognosis [25, 27].
In this study, we show that patients with luminal tu-
mours and higher expression of PPFIA1 are less likely to
benefit from endocrine therapy. High PPFIA1 expression
predicted higher probability of relapse in patients who
were given endocrine treatment. These findings suggest
that PPFIA1 expression could provide complementary
information to currently existing ER expression to pre-
dict failure of endocrine treatment, and could easily be
routinely measured by the conventional IHC. However,
further studies of pre-clinical and clinical are required to
confirm and validate the clinical value of PPFI1 as pre-
dictive marker, particularly as the exact relationship be-
tween PPFIA1 and hormonal signals remains unclear.
PPFIA1 is located at the 11q13 amplification region,
which occurs in about 20% of breast tumours [11].
CCND1 is the important driver gene of the 11q13 ampli-
con, and PPFIA1 amplification was found in all CCND1-
amplified breast cancers [11, 18]. We have demonstrated
that PPFIA1 mRNA was positively correlated with
CCND1 mRNA levels in cases with luminal tumours.
Previous studies found that high CCND1 expression and
amplification associates with an impaired response to
tamoxifen treatment and high risk of relapse in luminal
breast cancer [28, 29]. Taken together, these findings
might suggest a role on how PPFIA1 expression associ-
ates with poor response to endocrine therapy.
Previous studies suggested that integrin signalling
might have a significant role in cell migration and inva-
sion, and also in modulating resistance to anti-cancer
treatments [30, 31]. In the current study, we found a
correlation between PPFIA1 mRNA expression and in-
tegrin family members in luminal breast cancer. Our
finding supports previous studies that reported PPFIA1
as an essential regulator of integrin signalling which re-
quired for efficient cell motility [20, 32]. Further, we
found that high PPFIA1 expression is negatively associ-
ated with the tumour metastasis suppressor gene
(CD82), which is suggested to inhibit cell migration and
invasion via regulating the integrin-mediated signalling
[33]. In breast tumours, CD82 reduces in vitro migration
and in vivo metastasis [34]. In line with our finding,
Table 1 Multivariate cox analysis of associations between
PPFIA1 protein expression and clinicopathological parameters in
luminal breast cancer
Luminal breast cancer cohort
Recurrence free survival
HR (95% CI) P P*
PPFIA1 1.7 (1.1–2.6) 0.004 0.01
Tumour size 1.4 (1.1–1.9) 0.031 0.038
Tumour grade 1.3 (1.1–1.6) 0.017 0.02
Nodal stage 1.4 (1.1–1.8) 0.001 0.005
Distant metastasis free survival
HR (95% CI) P P*
PPFIA1 1.4 (0.9–2.1) 0.05 0.06
Tumour size 1.7 (1.2–2.4) 0.001 0.002
Tumour grade 1.4 (1.1–1.8) 0.003 0.005
Nodal stage 1.5 (1.1–1.9) 0.0007 0.003
Breast cancer specific survival
HR (95% CI) P P*
PPFIA1 1.6 (1.1–2.6) 0.02 0.025
Tumour size 1.8 (1.3–2.7) 0.0008 0.001
Tumour grade 1.7 (1.3–2.3) 0.00004 0.0002
Nodal stage 1.5 (1.2–2.0) 0.0007 0.001
Endocrine-treated cohort
Recurrence free survival
HR (95% CI) P P*
PPFIA1 2.5 (1.3–5.0) 0.006 0.01
Tumour size 2.0 (1.2–3.5) 0.0053 0.01
Tumour grade 1.5 (1.0–2.3) 0.048 0.06
Nodal stage 1.7 (1.1–2.4) 0.0051 0.02
Distant metastasis free survival
HR (95% CI) P P*
PPFIA1 2.4 (1.2–4.7) 0.009 0.01
Tumour size 1.9 (1.1–3.2) 0.01 0.012
Tumour grade 2.0 (1.2–3.1) 0.002 0.005
Nodal stage 1.8 (1.2–2.6) 0.001 0.005
Breast cancer specific survival
HR (95% CI) P P*
PPFIA1 2.8 (1.3–5.8) 0.005 0.008
Tumour size 2.4 (1.3–4.1) 0.002 0.005
Tumour grade 2.6 (1.6–4.4) 0.0001 0.0005
Nodal stage 1.6 (1.1–2.5) 0.009 0.01
P*: Adjusted p-value
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silencing of PPFIA1 was found to upregulate the CD82
cell surface protein in breast tumours [21]. Altogether,
these findings suggest that PPFIA1 could potentially act
as in regulating CD82 expression and integrin signalling
causing tumour progression and invasion in luminal
breast cancer.
PPFIBPI, also known as liprin-β1, is a member of
liprin family, and is one of the many binding partners of
PPFIA1. A previous study showed that silencing of
PPFIBPI causes a significant decrease of cell migration
and it was demonstrated that PPFIA1 and PPFIBPI may
co-operate in the regulation of tumour cell migration
[7]. In this study, a positive correlation was observed be-
tween PPFIA1 and PPFIBPI in patients with luminal
breast cancer, which may confirm their regulatory roles
in the migration of tumour cells.
Conclusions
This study provides evidence for the role of PPFIA1 expres-
sion in luminal breast cancer. Most importantly, our study
has clearly showed that PPFIA1 expression is a potential
marker for poor benefit from endocrine therapy and its
measurement may guide the clinician for alternative therapy.
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